We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Chiral Quest Subsidiary Signs License Agreement with

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

VioQuest's subsidiary Chiral Quest, Inc., (VQPH) signed a licensing agreement granting Merck & Co., Inc. use of its catalysts for the process development and manufacture of single-enantiomer intermediates and active pharmaceutical ingredients.


This agreement provides Merck with access to a broad range of proprietary ligands and catalysts.